Document is current
Any future updates will be listed below
-
Authors
Louros, Nikolaos https://orcid.org/0000-0002-4030-1022
Ramakers, Meine
Michiels, Emiel
Konstantoulea, Katerina https://orcid.org/0000-0002-0960-6274
Morelli, Chiara
Garcia, Teresa
Moonen, Nele
D’Haeyer, Sam https://orcid.org/0000-0002-0090-3854
Goossens, Vera
Thal, Dietmar Rudolf https://orcid.org/0000-0002-1036-1075
Audenaert, Dominique
Rousseau, Frederic https://orcid.org/0000-0002-9189-7399
Schymkowitz, Joost https://orcid.org/0000-0003-2020-0168
- License Information
-
More Information
Article History
Received: 11 August 2021
Accepted: 11 February 2022
First Online: 15 March 2022
Competing interests
: N.L., E.M., J.S. and F.R. are listed as inventors of a patent held by their hold institution VIB (patent application number - WO2021229102), covering the methodology described in this manuscript for the development of structure-based amyloid inhibitors. D.R.T. received speaker honorarium from Novartis Pharma Basel (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK), and UCB (Belgium), and collaborated with GE-Healthcare (UK), Novartis Pharma Basel (Switzerland), Probiodrug (Germany) and Janssen Pharmaceutical Companies (Belgium). The other authors declare no conflicts of interest.
